Abstract
To inform drug formulary decision-making, US reimbursement authorities commonly require budget impact analyses (BIA), typically reported as budget impact (BI) per member per month (PMPM). However, proper interpretation of BI PMPM is hampered by the lack of accepted pre-specified PMPM thresholds defining a financially acceptable BI. We updated a prior systematic review of published US BIA to establish PMPM benchmarks and assess how BIA authors qualitatively interpreted their own results.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
